Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.68 |
| ▸ | IMPDH2 | P12268 | 7/20 | 0.68 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.68 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.64 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.64 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.59 |
| ▸ | HINT1 | P49773 | 1/20 | 0.59 |
| ▸ | KRAS | P01116 | 6/20 | 0.58 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10037916 | 1.00 | NT5E (0.68) | NT5EIMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL10067882 | 1.00 | NT5E (0.68) | NT5EIMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL13638722 | 1.00 | NT5E (0.68) | NT5EIMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL9976681 | 1.00 | NT5E (0.68) | NT5EIMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL5827788 | 0.93 | TGM2 (0.69) | NT5EIMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL5827796 | 0.93 | TGM2 (0.69) | NT5EIMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL25070726 | 0.93 | TGM2 (0.66) | NT5EIMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL29092996 | 0.93 | NT5E (0.66) | NT5EIMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL720437 | 0.93 | TAS1R3 (0.70) | NT5EIMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL14576179 | 0.93 | TAS1R3 (0.70) | NT5EIMPDH2IMPDH1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717779-A2 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TriLink BioTechnologies, LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4276189-B1 | INITIATING CAPPED OLIGONUCLEOTIDE PRIMERS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4424835-B1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4658772-A1 | IN VITRO TRANSCRIPTION METHODS AND COMPOUNDS FOR USE THEREIN | Genscript USA Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250171489-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES, LLC (US) | 2025-05-29 | — | — | US | disclosed |
| US-12258369-B2 | Compositions and methods for synthesizing 5′-capped RNAs | TRILINK BIOTECHNOLOGIES, LLC (US) | 2025-03-25 | — | — | US | disclosed |
| US-12103944-B2 | Compositions and methods for synthesizing 5′-capped RNAs | TRILINK BIOTECHNOLOGIES, LLC (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4424835-A2 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TriLink BioTechnologies, LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024163689-A1 | IN VITRO TRANSCRIPTION METHODS AND COMPOUNDS FOR USE THEREIN | GENSCRIPT USA INC. (US) | 2024-08-08 | — | — | WO | disclosed |
| US-20240158433-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES, LLC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-3352584-B1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES LLC (US) | 2021-05-12 | — | — | EP | disclosed |
| US-10913768-B2 | Compositions and methods for synthesizing 5′-capped RNAs | TRILINK BIOTECHNOLOGIES, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10519189-B2 | Compositions and methods for synthesizing 5′-Capped RNAs | TRILINK BIOTECHNOLOGIES, INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-10494399-B2 | Compositions and methods for synthesizing 5′-Capped RNAS | TRILINK BIOTECHNOLOGIES, INC. (US) | 2019-12-03 | — | — | US | disclosed |
| US-20190270766-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES, INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190144490-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-20180273576-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-20060252115-A1 | Synthesis and use of anti-reverse mRNA cap analogues | DARZYNKIEWICZ EDWARD | 2006-11-09 | — | — | US | disclosed |
| US-7074596-B2 | Synthesis and use of anti-reverse mRNA cap analogues | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2006-07-11 | — | — | US | disclosed |
| US-20030194759-A1 | Synthesis and use of anti-reverse mRBA cap analogues | DARZYNKIEWICZ, EDWARD (PL) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252115-A1 | Synthesis and use of anti-reverse mRNA cap analogues | RNGTT, RNMT, CPSF6 | NT5E 486/4885IMPDH2 861/4885IMPDH1 640/4885 |
| US-12258369-B2 | Compositions and methods for synthesizing 5′-capped RNAs | RNGTT, RNMT, NT5C3B | NT5E 32/4885IMPDH2 266/4885IMPDH1 224/4885 |
| US-10494399-B2 | Compositions and methods for synthesizing 5′-Capped RNAS | RNGTT, RNMT, NT5C3B | NT5E 32/4885IMPDH2 266/4885IMPDH1 224/4885 |
| US-20180273576-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | RNGTT, RNMT, NT5C3B | NT5E 29/4885IMPDH2 262/4885IMPDH1 218/4885 |
| US-10913768-B2 | Compositions and methods for synthesizing 5′-capped RNAs | RNGTT, RNMT, NT5C3B | NT5E 32/4885IMPDH2 266/4885IMPDH1 224/4885 |
| US-10519189-B2 | Compositions and methods for synthesizing 5′-Capped RNAs | RNGTT, RNMT, NT5C3B | NT5E 32/4885IMPDH2 266/4885IMPDH1 224/4885 |
| US-12103944-B2 | Compositions and methods for synthesizing 5′-capped RNAs | RNGTT, RNMT, NT5C3B | NT5E 32/4885IMPDH2 266/4885IMPDH1 224/4885 |
| US-20250171489-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | RNGTT, RNMT, NT5C3B | NT5E 29/4885IMPDH2 262/4885IMPDH1 218/4885 |
| US-20190144490-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | RNGTT, RNMT, NT5C3B | NT5E 29/4885IMPDH2 262/4885IMPDH1 218/4885 |
| US-20240158433-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | RNGTT, RNMT, NT5C3B | NT5E 29/4885IMPDH2 262/4885IMPDH1 218/4885 |
| US-20190270766-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | RNGTT, RNMT, NT5C3B | NT5E 29/4885IMPDH2 262/4885IMPDH1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.